Research Paper Volume 15, Issue 12 pp 5355—5380
Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer
Figure 5. The validation of the prognosis value of BCRS in BLCA. (A) The hazard ratios and the 95% confidence intervals of the variables in the predictive model. (B) A nomogram was drawn to visualize the predictive model. (C–F) The distribution of the BCRSs and survival statuses of the BLCA cases from the TCGA-BLCA cohort (C), the GSE13507 cohort (D), the GSE31684 cohort (E), and the GSE32894 cohort (F). The cut-off values to divide all the subjects in these cohorts into low- and high-BCRS subgroup was equal to 2.75, which was detected by X-tile in the training cohort. (G–J) The Kaplan-Meier survival analyses of BCRS in the TCGA-BLCA cohort (G), the GSE13507 cohort (H), the GSE31684 cohort (I), and the GSE32894 cohort (J). (K–N) The association between the survival statuses and BCRS stratification in the TCGA-BLCA cohort (K), the GSE13507 cohort (L), the GSE31684 cohort (M), and the GSE32894 cohort (N). BCRS, B cell-related score.